Lameplast’s offer of containers for ophthalmic use continues to grow. In order to make the use of ophthalmic formulations even more practical and efficient, the company situated in Rovereto sulla Secchia has created a 10ml plastic bottle compatible with Aptar’s OSD (Ophthalmic Squeeze Dispenser) device.
The OSD is today widely used for ophthalmic products intended for the treatment of eye dryness or other chronic diseases such as glaucoma. The easy-to-use device is a state-of-the-art solution that allows eliminating preservatives, often blamed for causing eye allergies and irritations in sensitive subjects or who have to use eye drops for long periods of time or treatments. This new bottle is made of pharmaceutical-grade PE, sterilized by gamma-ray and is available in a neutral colour and soon also in white.
A palette of colours personalizes containers for pharmaceutical and medical use
Today, containers for pharmaceutical and medical use are coloured too. Lameplast offers a new possibility to personalize containers thanks to the use of safe pigments in compliance with the European Pharmacopoeia, 9th edition.
The Lameplast single-dose is smarter than ever: now with built-in applicator
The Lameplast single-dose is smarter than ever. Not only does it team practicality, safety and the right quantity of product; it also now comes with an applicator. For optimised results and to encourage correct product application, the applicator can be offered in a variety of versions.
Lameplast's new entry for winter 2018: Pentafill A25, the latest sterile filling technology and innovation
Increasingly dedicated and appealing products, increasingly diversified services. Lameplast is the corporate embodiment of the single-dose units. Not only can Lameplast boast an original pack, then, but also innovative filling, now specifically conceived for sterile filling.
Future and innovation: Lameplast Group opens up to Aksìa investors
To face the challenges of the future and make a qualitative leap on a global scale, Lameplast Group grows stronger with the entry of private equity fund Aksìa Group SGR, which has acquired 100% of the Group. The acquisition covers the three companies, Lameplast, COC Farmaceutici and the subsidiary LF of America, the overseas division based in Miami.
Lameplast anticipates the future of pharmaceutical packaging and embraces new investment
With over 40 years in the pharmaceutical packaging industry, Lameplast Group is actively looking to the future. So far, 2017 has seen the company grow ever stronger with the investment of Aksìa as the company embraces the globe with its new partners and continues to anticipate pharma packaging requirements. Barbara Reguzzoni explains what is happening.
Lameplast launches new single-dose strip with large area closing system
A new single-dose that allows storing an extensive amount of information. This is the latest breakthrough from Lameplast Group which, to cater to new market demands and increasingly more stringent international regulations, is launching its single-dose strip with even more space at disposal for printing and for the inclusion of product information.
Fratelli Carli's Mediterranea brand chooses Lameplast Group's green single-dose for new Olive line
The future of packaging is looking increasingly greener and more practical. That's why Fratelli Carli's Mediterranea brand has chosen the Lameplast Group's injection-molded single-dose container in Green Polyethylene (Bio PE) for its new 'Olive' cosmetic line which features a strip of five 10ml sized white single-dose reclosable containers, printed with bioplastics of vegetable origin.
Lameplast celebrates 40 years of research and innovation
On Friday 27 May, Lameplast celebrated its first 40 years with a big event attended by its founding partners – Giovanni Ferrari, Evro Fabbri and Antonio Fontana –, the authorities, employees and a number of international clients at its headquarters in Rovereto sulla Secchia. The event was an opportunity to remember the birth of the company, an experience that, thanks to the entrepreneurship of its founding partners, Giovanni Ferrari, Evro Fabbri and Antonio Fontana, has led to the innovation and excellence of Made in Italy around the world.
Barbara Reguzzoni provides an insight into Lameplast Group
Lameplast Group's Barbara Reguzzoni speaks to Webpackaging about its 40 years of expertise in the pharmaceutical industry and how the company has developed from its beginnings as a manufacturer to the complete service provider which it is today.
Lameplast Group's entire range can now be moulded in Bioplastic
The future of packaging? It's green! And so is the future of marketing. After launching the first injection molded single-dose in Green Polyethylene (Bio PE), Lameplast Group is now able to offer a full range of bioplastic containers made from raw vegetal materials as an alternative to those made from oil-based plastic. Bioplastic is a 100% renewable source unlike oil-based plastic.
Lameplast Group's Pentafill: The single-dose worldwide experience
With more than 35 years experience and millions of single-dose units produced and filled for the biggest names in pharmaceuticals and cosmetics, Lameplast Group is the most reliable manufacturer of its kind on the single-dose packaging market. Now the Group presents an even more comprehensive service, offering customers the opportunity to carry out their own final packaging, from wherever they operate with the Pentafill range.
Preservative-free ophthalmic preparations also in multidose bottles
Preservatives are a well-known drawback for ophthalmic preparations. This is why Lameplast Group has expanded the range of services offering production, filling and packaging services for preservative-free ophthalmic products also in multidose bottles thanks to its partnership with Aptar Pharma.
Lameplast Group is a member of Acticospack: a project to reduce or eliminate preservatives in packaging technology
Preservatives are used nowadays in a large number of cosmetic, pharmaceutical, and food products. The most used are the parabens which are currently under revision in Europe. As consequence of evaluations of the existing safety data, the European Scientific Committees has recommended the reduction of the actual allowed contents.
- Elias Bittan
- Product Info
- Created 19 Sep 2018
- Modified 22 Jan 2020
- Hits 729